{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:21:35Z","timestamp":1790198495719,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Non-Hodgkin lymphoma is a malignancy of B lymphocytes that typically infiltrate sites of disease, including the lymph nodes, spleen, and bone marrow. Beyond the presence of malignant cells, many immune cells are also present within the tumor microenvironment. Although these immune cells have the potential to regulate the growth of malignant B cells, intratumoral immune cells are unable to eradicate lymphoma cells and most patients with lymphoma have clinical evidence of disease progression. Recent data have identified some of the mechanisms that account for the suppressed antitumor immune response and have created opportunities for treatment to overcome the deficiencies. Two general categories of immunological therapies are available. The first approach is to use agents that prevent inhibitory signals via immune checkpoint receptors that downregulate immune cell function. Blockade of suppressive programmed cell death 1 (PD-1) or CTLA-4 signaling has resulted in significant clinical activity by allowing intratumoral T cells to remain activated and target malignant cells. A second approach is to additionally activate T cells that are suboptimally active or suppressed, by providing signals through costimulatory molecules including CD27 or CD40 or by adding immunostimulatory cytokines. There has been significant heterogeneity in the responses to these treatment approaches. Clinical responses are seen in many diseases, but the most promising responses have been with PD-1 blockade in Hodgkin lymphoma. In other lymphomas, responses are seen but only in a subset of patients. Further research is needed to identify the mechanisms that account for response and to identify patients most likely to benefit from immune modulation.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.618","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:11Z","timestamp":1555452791000},"page":"618-621","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond"],"prefix":"10.1182","volume":"2017","author":[{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2019111703525260600_B1","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.3109\/10428194.2015.1011640","article-title":"T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion","volume":"56","author":"Yang","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111703525260600_B2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2019111703525260600_B3","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1111\/febs.13668","article-title":"Immune checkpoint blockade in lymphoid malignancies","volume":"283","author":"Thanarajasingam","year":"2016","journal-title":"FEBS J"},{"key":"2019111703525260600_B4","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation-2015.1.69","article-title":"Checkpoint blockade in lymphoma","author":"Armand","year":"2015"},{"issue":"4","key":"2019111703525260600_B5","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J Clin Invest"},{"issue":"3","key":"2019111703525260600_B6","doi-asserted-by":"crossref","first-page":"e59456","DOI":"10.1371\/journal.pone.0059456","article-title":"Soluble and membrane-bound TGF-\u03b2-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"issue":"23","key":"2019111703525260600_B7","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111703525260600_B8","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/leu.2016.385","article-title":"Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients","volume":"31","author":"Rossille","year":"2017","journal-title":"Leukemia"},{"issue":"19","key":"2019111703525260600_B9","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111703525260600_B10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd3877","article-title":"Advances in targeting cell surface signalling molecules for immune modulation","volume":"12","author":"Yao","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2019111703525260600_B11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/imr.12523","article-title":"Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the yin to the yang of cancer immunotherapy","volume":"276","author":"Kean","year":"2017","journal-title":"Immunol Rev"},{"issue":"13","key":"2019111703525260600_B12","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-09-0266","article-title":"Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin\u2019s lymphoma","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res"},{"issue":"12","key":"2019111703525260600_B13","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol"},{"issue":"14","key":"2019111703525260600_B14","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-11-3308","article-title":"Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia","volume":"18","author":"Vitale","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2019111703525260600_B15","author":"Ansell","year":"2014"},{"issue":"26","key":"2019111703525260600_B16","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2008.21.3017","article-title":"Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Advani","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111703525260600_B17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-8722-7-44","article-title":"A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors","volume":"7","author":"de Vos","year":"2014","journal-title":"J Hematol Oncol"},{"key":"2019111703525260600_B18","author":"Gopal","year":"2015"},{"issue":"20","key":"2019111703525260600_B19","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"31","key":"2019111703525260600_B20","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111703525260600_B21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111703525260600_B22","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111703525260600_B23","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111703525260600_B24","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"22","key":"2019111703525260600_B25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/618\/1249584\/hem00083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/618\/1249584\/hem00083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:53:06Z","timestamp":1573980786000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/618\/21055\/Harnessing-the-power-of-the-immune-system-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.618","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}